Loading candles…
Eris Lifesciences Ltd operates in the pharmaceutical industry in India, focusing on the manufacture and marketing of domestic pharmaceutical formulations. The company’s portfolio includes products in cardiology, diabetes, gastroenterology, dermatology, as well as medical aesthetics and injectables. Its business model centers on a pure-play domestic formulations strategy supported by a field force that engages with super-specialist and specialist doctors. Eris Lifesciences has established a strong market position in the chronic segment, which constitutes a significant portion of its revenue. There is no publicly available information regarding its incorporation year, founders, key management, subsidiaries, or stock exchange listings.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 20 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 13 Feb 2026 |
| Other | To consider issuance of equity shares of the Company by way of a preferential issue | 24 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 12 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 5 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 19 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.